Drug Profile
LNP 1892
Alternative Names: LNP1892Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Lupin
- Class
- Mechanism of Action Calcium-sensing receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperparathyroidism
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I for Hyperparathyroidism (In volunteers) in United Kingdom (PO)
- 29 Sep 2021 Discontinued - Phase-II for Hyperparathyroidism in India (PO)
- 13 Jun 2019 Lupin completes enrolment in its phase II trial for Hyperparathyroidism in India (PO) (CTRI/2017/07/009179)